Citations

Clear

4308 citation(s) found for "Yu, Jeffrey".

Clinical Elements that Predict Outcome after Traumatic Brain Injury: A Prospective Multicenter Recursive Partitioning (Decision-Tree) Analysis
Brown, Allen W. , Malec, James F. , McClelland, Robyn L. , Diehl, Nancy N. , Englander, Jeffrey, Cifu, David X.

Mayo Clinic

Journal of Neurotrauma | October 20, 2005 | Volume: 22 | Issue: 10 | Pages: 1040-1051

10.1089/neu.2005.22.1040 | PMID 16238482 Get It

The NHLBI Lymphangioleiomyomatosis Registry
Ryu, Jay H. , Moss, Joel , Beck, Gerald J. , Lee, Jar-Chi, Brown, Kevin K. , Chapman, Jeffrey T., Finlay, Geraldine A., Olson, Eric J. , Ruoss, Stephen J. , Maurer, J.R., Raffin, Thomas A., Peavy, Hannah, Taveira‐DaSilva, Angelo M., McCormack, Francis X. , Avila, Nilo A., DeCastro, Rosamma, Jacobs, Susan S. , Stylianou, Mario, Fanburg, Barry L., Lee, Jar-Chi, McCarthy, Kevin , McCormack, Francis X , Ryu, Jay H

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | October 6, 2005 | Volume: 173 | Issue: 1 | Pages: 105-111

10.1164/rccm.200409-1298oc | PMID 16210669 Get It

Abstract Rationale Pulmonary lymphangioleiomyomatosis is a progressive cystic lung disease that is associated with infiltration of atypical smooth muscle–like cells. Previous descriptions of clinical characteristics of subjects with lymphangioleiomyomatosis have been based on a limited number of patients. Objectives To describe the clinical characteristics of subjects with pulmonary lymphangioleiomyomatosis, both sporadic and tuberous sclerosis–related forms. Methods Over a 3-yr period, from 1998 to 2001, 243 subjects with pulmonary lymphangioleiomyomatosis were enrolled into a national registry; 13 subjects who had already undergone lung transplantation were excluded for the purposes of this report. Measurements and Main Results All 230 subjects were women, aged 18 to 76 yr (mean ± SE, 44.5 ± 0.65 yr). The average age at onset of symptoms was 38.9 ± 0.73 yr and at diagnosis was 41.0 ± 0.65 yr. Tuberous sclerosis complex was present in 14.8% of subjects. Pulmonary manifestations, most commonly spontaneous pneumothorax, were the primary events leading to the diagnosis in 86.5% of cases. Nearly 55% of the subjects were being treated with a progesterone derivative. An obstructive pattern on pulmonary function testing was observed in 57.3% of the subjects, whereas 33.9% had normal spirometric results. Women with tuberous sclerosis–related lymphangioleiomyomatosis were younger and had less impaired lung function compared with those with the sporadic form. Conclusions The age range of women afflicted with pulmonary lymphangioleiomyomatosis is broader than previously appreciated and the degree of pulmonary function can be quite variable, with one-third of subjects having normal spirometry at enrollment into this registry.
Satisfaction After Contralateral Prophylactic Mastectomy: The Significance of Mastectomy Type, Reconstructive Complications, and Body Appearance
Frost, Marlene H., Slezak, Jeffrey M., Tran, Nho V. , Williams, Constance I., Johnson, Joanne L., Woods, John E., Petty, Paul M., Donohue, John H., Grant, Clive S., Sloan, Jeff A. , Sellers, Thomas A. , Hartmann, Lynn C.

Mayo Clinic

Journal of Clinical Oncology | October 4, 2005 | Volume: 23 | Issue: 31 | Pages: 7849-7856

10.1200/jco.2005.09.233 | PMID 16204003 Get It

Purpose Contralateral prophylactic mastectomy (CPM) is one option for reducing the risk of a second breast cancer in women with a personal and family history of breast cancer. Few data are available regarding satisfaction, psychological, and social function after CPM. The purpose of this research is to evaluate women’s long-term satisfaction with CPM, factors influencing satisfaction, and psychological and social function after CPM. Patients and Methods This was a descriptive study of all women with a family history of breast cancer, known to be alive, who elected CPM at Mayo Clinic (Rochester, MN) between 1960 and 1993 (n = 621). Ninety-four percent of the women (n = 583) completed a study-specific questionnaire. Results A mean of 10.3 years after the procedure, the majority of women (83%) were satisfied with their CPM. A smaller number were neutral (8%) or dissatisfied (9%). Women who had a subcutaneous mastectomy had more problems with reconstruction, and fewer of these women were satisfied than women with simple mastectomy. Decreased satisfaction with CPM was associated with decreased satisfaction with appearance, complications with reconstruction, reconstruction after CPM, and increased level of stress in life. The majority of women experienced no change or favorable effects in self-esteem (83%), level of stress in life (83%), and emotional stability (88%). Satisfaction with body appearance, feelings of femininity, and sexual relationships were the most adversely affected with 33%, 26%, and 23% of the women responding negatively. Conclusion Although most women are satisfied with CPM, each woman should weigh the benefits alongside the potential adverse effects.
Proceedings of the Third International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer
Come, Steven E. , Buzdar, Aman U. , Arteaga, Carlos L. , Bissell, Mina J. , Brown, Myles , Goss, Paul E. , Green, Jeffrey E., Medina, Daniel , Nicholson, Robert I., Santen, Richard J. , Hart, Carol S. , Ellis, Matthew J. , Ingle, James N. , Lee, Adrian V. , Schiff, Rachel , Brown, Myles

Mayo Clinic

Clinical Cancer Research | September 21, 2005 | Volume: 10 | Issue: 1 | Pages: 327s-330s

10.1158/1078-0432.ccr-031213 | PMID 14734487 Get It

Phase 1 Trial of Flavopiridol Combined with Cisplatin or Carboplatin in Patients with Advanced Malignancies with the Assessment of Pharmacokinetic and Pharmacodynamic End Points
Bible, Keith C. , Lensing, Janet L., Nelson, Sacha A., Ames, Matthew M. , Isham, Crescent R., Piens, Jill, Rubin, Stacie L., Rubin, Joseph, Kaufmann, Scott H. , Atherton, Pamela J. , Sloan, Jeffrey A., Daiss, Michelle K., Adjei, Alex A. , Erlichman, Charles , Lee, Yean Kee , Reid, Joel M. , Kaufmann, Scott H

Mayo Clinic

Clinical Cancer Research | September 21, 2005 | Volume: 11 | Issue: 16 | Pages: 5935-5941

10.1158/1078-0432.ccr-04-2566 | PMID 16115936 Get It

Abstract Purpose: Flavopiridol, a cyclin-dependent kinase inhibitor, transcription inhibitor, and DNA-interacting agent, was combined with cisplatin or carboplatin to establish toxicities, evaluate pharmacokinetics, and examine its effects on patient cancers and levels of selected polypeptides in patient peripheral blood mononuclear cells (PBMC). Experimental Design: Therapy was given every 3 weeks. Stage I: cisplatin was fixed at 30 mg/m2 with escalating flavopiridol. Stage II: flavopiridol was fixed at the stage I maximum tolerated dose (MTD) with escalation of cisplatin. Stage III: flavopiridol was fixed at the stage I MTD with escalation of carboplatin. Results: Thirty-nine patients were treated with 136 cycles of chemotherapy. Neutropenia was seen in only 11% of patients. Grade 3 flavopiridol/CDDP toxicities were nausea (30%), vomiting (19%), diarrhea (15%), dehydration (15%), and neutropenia (10%). Flavopiridol combined with carboplatin resulted in unexpectedly high toxicities and one treatment-related death. Stable disease (>3 months) was seen in 34% of treated patients, but there were no objective responses. The stage II MTD was 60 mg/m2 cisplatin and 100 mg/m2/24 hours flavopiridol. As given, CDDP did not alter flavopiridol pharmacokinetics. Flavopiridol induced increased p53 and pSTAT3 levels in patient PBMCs but had no effects on cyclin D1, phosphoRNA polymerase II, or Mcl-1. Conclusions: Flavopiridol and cisplatin can be safely combined in the treatment of cancer patients. Unexpected toxicity in flavopiridol/carboplatin-treated patients attenuates enthusiasm for this alternative combination. Analysis of polypeptide levels in patient PBMCs suggests that flavopiridol may be affecting some, but not all, of its known in vitro molecular targets in vivo.
Gene Expression Profiles Predict Early Relapse in Ovarian Cancer after Platinum-Paclitaxel Chemotherapy
Hartmann, Lynn C. , Lu, Karen H. , Linette, Gerald P. , Cliby, William A. , Kalli, Kimberly R., Bast, Robert C. , Stec, James , Iartchouk, Natalia, Smith, David I., Hoersch, Sebastian, Shridhar, Viji , Lillie, James W., Clark, Edwin, Damokosh, Andrew I., Gershenson, David M. , Smith, David I., Ross, Jeffrey S. , Kaufmann, Scott H. , Bast, Robert C

Mayo Clinic

Clinical Cancer Research | September 21, 2005 | Volume: 11 | Issue: 6 | Pages: 2149-2155

10.1158/1078-0432.ccr-04-1673 | PMID 15788660 Get It

Abstract Purpose: Women with advanced epithelial ovarian cancer are routinely treated with platinum-paclitaxel chemotherapy following cytoreductive surgery, yet only ∼20% achieve long-term disease-free survival. We hypothesized that differences in gene expression before treatment could distinguish patients with short versus long time to recurrence after administration of platinum-paclitaxel combination chemotherapy. Experimental Design: To test this hypothesis, gene expression profiling of 79 primary surgically resected tumors from women with advanced-stage, high-grade epithelial ovarian cancer was done using cDNA microarrays containing 30,721 genes. Supervised learning algorithms were applied in an effort to develop a binary classifier that could discriminate women at risk for early (≤21 months) versus late (>21 months) relapse after initial chemotherapy. Results: A 14-gene predictive model was developed using a set of training samples (n = 51) and subsequently tested using an independent set of test samples (n = 28). This model correctly predicted the outcome of 24 of the 28 test samples (86% accuracy) with 95% positive predictive value for early relapse. Conclusions: Predictive markers for early recurrence can be identified for platinum-paclitaxel combination chemotherapy in primary ovarian carcinoma. The proposed 14-gene model requires further validation.
Associations between Plasma Insulin-Like Growth Factor Proteins and C-Peptide and Quality of Life in Patients with Metastatic Colorectal Cancer
Meyerhardt, Jeffrey A. , Sloan, Jeffrey A., Sargent, Daniel J. , Goldberg, Richard M. , Pollak, Michaël , Morton, Roscoe F., Ramanathan, Ramesh K., Williamson, Stephen K. , Findlay, B., Fuchs, Charles S. , Sargent, Daniel J , Williamson, Stephen , Pollak, Michael N , Meyerhardt, Jeffrey A

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | September 20, 2005 | Volume: 14 | Issue: 6 | Pages: 1402-1410

10.1158/1055-9965.epi-04-0862 | PMID 15941948 Get It

Abstract Objective: Predictors of quality of life (QOL) in patients with metastatic colorectal cancer are lacking. The insulin-like growth factor (IGF) family of proteins is associated with QOL in noncancer populations. We sought to study whether these proteins are associated with QOL in patients with colorectal cancer. Method: We used a cohort of 526 patients with metastatic colorectal cancer treated with combination chemotherapy. Plasma samples of IGF-I, IGF-II, IGF binding protein-3, and C-peptide were collected before initiation of chemotherapy. QOL was measured by the uniscale instrument and the Symptom Distress Scale at baseline and throughout treatment. Results: Baseline plasma levels of IGF-I and IGF-II before initiation of chemotherapy were significantly associated with several important baseline QOL measures in patients with metastatic colorectal cancer. Patients with lower levels of IGF-I reported increased distress with regard to appearance, appetite, cough, and nausea intensity after adjustment for potential confounders. Similarly, decreased levels of IGF-II were predictive of worse quality related to appearance, appetite, fatigue, nausea frequency and intensity, pain frequency, and composite Symptom Distress Scale score. IGF binding protein-3 and C-peptide were not predictive of baseline QOL. Baseline biomarkers were not associated with subsequent changes in QOL during treatment. Higher body mass index was significantly associated with superior baseline QOL in several areas; nonetheless, the association of IGF-I and IGF-II with baseline QOL measures remained significant even after controlling for baseline body mass index. Conclusion: Baseline plasma IGF-I and IGF-II are significantly associated with symptom distress. Whether this association is simply reflective of patient nutritional status and/or disease burden or represents an independent biological effect of IGFs on QOL remains uncertain. Nonetheless, these data suggest that molecular biomarkers may be useful predictors of QOL in cancer patients.
[O1‐04‐04]: Operational criteria for patient recruitment in trials of mild cognitive impairment
Petersen, Ronald , Thomas, Ronald G. , Grundman, Michael, Pfeiffer, Eric, Sano, Mary , Dyck, Christopher H. van , Thal, Leon J., Bennett, David A. , Kaye, Jeffrey , Levey, Allan I.

Mayo Clinic

Alzheimer's & Dementia | August 25, 2005 | Volume: 1 | Issue: 1S_Part_3 | Pages: No page available

10.1016/j.jalz.2005.06.303 Get It

Preserving Olfactory Function in Anterior Craniofacial Surgery through Cribriform Plate Osteotomy Applied in Selected Patients
Feiz‐Erfan, Iman , Han, Patrick P., Spetzler, Robert F., Horn, Eric M., Klopfenstein, Jeffrey D., Kim, Louis J. , Porter, Randall W., Beals, Stephen P., Lettieri, Salvatore C. , Joganic, Edward F., Kim, Louis J.

Mayo Clinic

Operative Neurosurgery | July 13, 2005 | Volume: 57 | Issue: suppl_1 | Pages: 86-93

10.1227/01.neu.0000163487.94463.4a | PMID 15987573 Get It

AbstractOBJECTIVE:Olfaction is often sacrificed to gain access to the cranial base in anterior craniofacial surgery. We describe the long-term results of olfactory function in patients who underwent anterior craniofacial surgery and a cribriform plate osteotomy to preserve olfaction.METHODS:Between 1992 and 2004, 28 patients underwent 29 cribriform plate osteotomies in an attempt to preserve olfaction during anterior craniofacial surgery performed through modified extended transbasal approaches. Patients' charts and office notes were reviewed retrospectively. Formal olfactory testing was available in 5 patients, but most data were based on patients' subjective reports of olfaction. Olfactory preservation was defined by the subjective ability to detect fumes such as coffee, chocolate, roses, and orange juice regardless of the intensity of the sensation. Follow-up was based on phone calls to patients.RESULTS:Four patients were lost to follow-up and excluded. Therefore, follow-up was available in 24 patients after 25 procedures. On the basis of patients' subjective reports, olfaction was spared in 22 patients after 23 procedures (92%) and was confirmed objectively in the five patients formally tested. After surgery, only two patients were anosmic.CONCLUSION:Olfaction can be preserved in selected patients undergoing anterior craniofacial surgery. At least 1 cm of nasal mucosa should remain attached to the cribriform plate, which can be achieved by including the nasal bone in the osteotomy of the orbital bar. A medial orbital canthopexy is therefore necessary after these procedures.